PIERIS expands IP in Anticalins
PIERIS has strengthened its patent estate for a new class of proteins which could represent a more flexible alternative to antibody-based drugs.
PIERIS has strengthened its patent estate for a new class of proteins which could represent a more flexible alternative to antibody-based drugs.
Applied Biosystems has unveiled a gene expression analysis product that allows researchers to conduct studies on the entire human genome using a single microarray.
Italy's Abiogen Pharma has licensed rights to two UK-developed compounds that seem to work via a completely new mechanism of action for the treatment of anxiety.
Tecan second-quarter results reveal some signs of recovery after a torrid first quarter and the departure of former chief executive Emile Sutcliffe, with diagnostics holding back an improved performance in biopharma.
The pharmaceutical industry is failing to increase efficiencies in core areas of its business - such as clinical trials and sales - because of an enormous pressure from investors to drive revenues, according to Datamonitor.